EYPT

Eyepoint Pharmaceuticals Inc

EYPT, USA

EyePoint Pharmaceuticals, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

https://eyepointpharma.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
EYPT
stock
EYPT

After Leaping 38% EyePoint, Inc. (NASDAQ:EYPT) Shares Are Not Flying Under The Radar simplywall.st

Read more →
EYPT
stock
EYPT

JonesTrading Maintains EyePoint(EYPT.US) With Buy Rating, Maintains Target Price $43 富途牛牛

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$35.5

Analyst Picks

Strong Buy

9

Buy

4

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

5.71

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-29.84 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-23.73 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-6,226.92 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.26

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 115.40% of the total shares of Eyepoint Pharmaceuticals Inc

1.

Cormorant Asset Management, LLC

(12.0779%)

since

2025/06/30

2.

Suvretta Capital Management, LLC

(9.8714%)

since

2025/06/30

3.

Adage Capital Partners Gp LLC

(9.8654%)

since

2025/06/30

4.

BlackRock Inc

(7.7766%)

since

2025/06/30

5.

Federated Hermes Inc

(6.6729%)

since

2025/06/30

6.

Franklin Resources Inc

(6.2401%)

since

2025/06/30

7.

Vanguard Group Inc

(5.5169%)

since

2025/06/30

8.

TCG Crossover Management, LLC

(5.1827%)

since

2025/06/30

9.

Citadel Advisors Llc

(3.401%)

since

2025/06/30

10.

Federated Hermes Kaufmann Growth

(2.9574%)

since

2025/06/30

11.

Federated Hermes Kaufmann R

(2.9574%)

since

2025/06/30

12.

Vanguard Total Stock Mkt Idx Inv

(2.9396%)

since

2025/07/31

13.

Franklin Biotechnology Discv A(acc)USD

(2.7745%)

since

2025/08/31

14.

Geode Capital Management, LLC

(2.3097%)

since

2025/06/30

15.

State Street Corp

(2.1988%)

since

2025/06/30

16.

iShares Russell 2000 ETF

(2.1563%)

since

2025/08/31

17.

Federated Hermes Kaufmann Small Cap A

(2.1544%)

since

2025/06/30

18.

Federated Hermes Kaufmann Small Cap Grow

(2.1544%)

since

2025/06/30

19.

Patient Square Capital

(1.9627%)

since

2025/06/30

20.

Goldman Sachs Group Inc

(1.858%)

since

2025/06/30

21.

Franklin US Small Cap Growth Equity

(1.8405%)

since

2025/06/30

22.

Franklin Small Cap Growth Adv

(1.6987%)

since

2025/07/31

23.

Essex Woodlands Health Ventures

(1.6972%)

since

2025/06/30

24.

5AM Venture Management, LLC

(1.5233%)

since

2025/06/30

25.

Franklin Biotechnology Discovery A

(1.5066%)

since

2025/07/31

26.

Aberdeen Group PLC

(1.4961%)

since

2025/06/30

27.

Bank of America Corp

(1.1812%)

since

2025/06/30

28.

Morgan Stanley - Brokerage Accounts

(1.1355%)

since

2025/06/30

29.

Vanguard Institutional Extnd Mkt Idx Tr

(1.0707%)

since

2025/07/31

30.

abrdn Healthcare Investors

(0.9796%)

since

2025/08/31

31.

HSBC Holdings PLC

(0.9156%)

since

2025/06/30

32.

Fidelity Small Cap Index

(0.9034%)

since

2025/06/30

33.

Federated Hermes MDT Small Cap Core IS

(0.9007%)

since

2025/06/30

34.

Federated Hermes MDT SCC Institutional

(0.9007%)

since

2025/06/30

35.

HSBC GIF Glb Eq Sust Hlthcare AC USD

(0.8724%)

since

2025/06/30

36.

Nantahala Capital Management, LLC

(0.8605%)

since

2025/06/30

37.

Allspring (Lux) WW Glb L/SEq IPUSD Acc

(0.8287%)

since

2025/01/31

38.

iShares Russell 2000 Value ETF

(0.7962%)

since

2025/08/31

39.

HBM Healthcare Investments AG Ord

(0.7254%)

since

2025/06/30

40.

Fidelity Extended Market Index

(0.5417%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.7481

Latest Release

Date

2025-09-30

EPS Actual

-0.85

EPS Estimate

-0.77

EPS Difference

-0.08

Surprise Percent

-10.3896%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2.5)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.